FIGURE 4.

mCuMV_TT‐RBM promotes IgA production and IgG responses are dominated with IgG2a subclass. A, RBD‐specific IgG titer for the groups vaccinated with CuMV_TT as a control or mCuMV_TT‐RBM on days 7, 14, 21, and 42 measured by ELISA OD₄₅₀. B, Log₁₀OD₅₀ of RBD‐specific IgG titers for the groups vaccinated with CuMV_TT or mCuMV_TT‐RBM on days 7, 14, 21 and 42 (Data from A). C, spike‐specific IgG titers for the groups vaccinated with CuMV_TT or mCuMV_TT‐RBM on days 7, 14, 21, and 42 measured by ELISA OD₄₅₀. D, Log₁₀OD₅₀ of spike‐specific IgG titers for the groups vaccinated with CuMV_TT or mCuMV_TT‐RBM on days 7, 14, 21, and 42 (Data from C). CuMV_TT n=5 and mCuMV_TT‐RBM n=10. E, RBD‐specific IgA titer for the groups vaccinated with CuMV_TT or mCuMV_TT‐RBM using D0/D14 or D0/D28 regimens, measured by ELISA OD₄₅₀. F, Log₁₀OD₅₀ of RBD‐specific IgA titer for the groups vaccinated with CuMV_TT or mCuMV_TT‐RBM using D0/D14 or D0/D28 regimens, sera of day 35 was used. CuMV_TT n=5 and mCuMV_TT‐RBM n=5. Statistical analysis (mean ±SEM) using one‐way ANOVA in B and D or Student's t test in F. One representative of 3 similar experiments is shown. The value of p<0.05 was considered statistically significant (*p<0.01, **p<0.001, ***p<0.0001)